Hims & Hers shares jump as FDA panel reviews peptide compounding

Hims & Hers Health Inc. surged 9.58% to $37.99 on Wednesday, the biggest intraday gain since the company announced a partnership with Novo Nordisk, as investors priced in the outcome of an FDA Pharmacy Compounding Advisory Committee meeting that could allow the firm to compound seven high‑demand peptides【2】.

FDA panel and peptide opportunity

The FDA is convening a two‑day panel to consider adding seven injectable peptides—including TB‑500 and BPC‑157—to the 503A Bulk List, a designation that would let state‑licensed compounding pharmacies produce them for Hims & Hers and other telehealth providers【3】. Analyst Allen Lutz of BofA Securities noted that inclusion would broaden the company’s “peptide optionality” and cited a large addressable market, while also warning that the advisory committee faces an “uphill battle” to shift the agency’s stance【2】. The meeting follows a recent FDA briefing that highlighted limited human data for the compounds, underscoring regulatory uncertainty【3】.

Market reaction and valuation shift

The regulatory focus sparked a sharp price rally, lifting Hims & Hers from a modest pre‑open level of $31.54 to $37.99—a 21% rise from the prior day’s close and a move that places the stock within striking distance of its 52‑week high of $70.43, though still well below that peak【4】. Analysts upgraded the stock to Neutral and raised price targets, with BofA lifting its target to $36 from $25 and Citigroup moving its rating from Sell to Neutral with a $24 target【1】【2】. Technical indicators show the RSI at 59.24 and a bullish MACD crossover, suggesting momentum could sustain the upside if the FDA decision is favorable【1】.

Competitive context and broader implications

Hims & Hers’ entry into peptide compounding would position it alongside other direct‑to‑consumer telehealth firms and high‑end longevity clinics that already market these substances despite limited clinical evidence【3】. The company’s chief medical officer, Dr. Anant Vinjamoori, emphasized a decade of experience with millions of patients, framing the potential regulatory change as a pathway to expand offerings beyond GLP‑1 weight‑loss drugs like Ozempic and Wegovy, which the firm recently added through its Novo Nordisk agreement【1】.

What to watch

• FDA PCAC decision: Outcomes from the July 23‑24 meeting could trigger a price reaction; a positive vote on any of the seven peptides would likely lift the stock further.
• Price resistance: Watch for a break above $38, which could test the $40‑$42 range that aligns with the stock’s recent upside momentum.
• Analyst revisions: Further upgrades or target adjustments from banks such as BofA or Citi may follow the regulatory verdict, providing additional price catalysts.

The market’s near‑term focus rests on whether the FDA will ease compounding restrictions, a move that could unlock a new revenue stream for Hims & Hers while reshaping the broader telehealth peptide landscape. The outcome remains uncertain, and the stock’s trajectory will hinge on the panel’s recommendations.